Retrospective cohort study to evaluate medication use in patients hospitalised with COVID-19 in Scotland : protocol for a national observational study

Mueller, Tanja and Kerr, Steven and McTaggart, Stuart and Kurdi, Amanj and Vasileiou, Eleftheria and Docherty, Annemarie and Fraser, Kenny and Shi, Ting and Simpson, Colin R and Bennie, Marion and Sheikh, Aziz (2021) Retrospective cohort study to evaluate medication use in patients hospitalised with COVID-19 in Scotland : protocol for a national observational study. BMJ Open, 11 (11). e054861. ISSN 2044-6055 (https://doi.org/10.1136/bmjopen-2021-054861)

[thumbnail of Mueller-etal-BMJO-2021-Retrospective-cohort-study-to-evaluate-medication-use-in-patients-hospitalised-with-COVID-19-in-Scotland]
Preview
 Text. Filename: Mueller_etal_BMJO_2021_Retrospective_cohort_study_to_evaluate_medication_use_in_patients_hospitalised_with_COVID_19_in_Scotland.pdf
Final Published Version
License: Creative Commons Attribution 4.0 logo
Download (409kB)| Preview

Abstract

Introduction COVID-19 has caused millions of hospitalisations and deaths globally. A range of vaccines have been developed and are being deployed at scale in the UK to prevent SARS-CoV-2 infection, which have reduced risk of infection and severe COVID-19 outcomes. Those with COVID-19 are now being treated with several repurposed drugs based on evidence emerging from recent clinical trials. However, there is currently limited real-world data available related to the use of these drugs in routine clinical practice. The purpose of this study is to address the prevailing knowledge gaps regarding the use of dexamethasone, remdesivir and tocilizumab by conducting an exploratory drug utilisation study, aimed at providing in-depth descriptions of patients receiving these drugs as well as the treatment patterns observed in Scotland. Methods and analysis Retrospective cohort study, comprising adult patients admitted to hospital with confirmed or suspected COVID-19 across five Scottish Health Boards using data from in-hospital ePrescribing linked to the Early Estimation of Vaccine and Anti-Viral Effectiveness (EAVE II) COVID-19 surveillance platform. The primary outcome will be exposure to the medicines of interest (dexamethasone, remdesivir, tocilizumab), either alone or in combination; exposure will be described in terms of drug(s) of choice; prescribed and administered dose; treatment duration; and any changes in treatment, for example, dose escalation and/or switching to an alternative drug. Analyses will primarily be descriptive in nature. Ethics and dissemination Ethical and information governance approvals have been obtained by the National Research Ethics Service Committee, South East Scotland 02 and the Public Benefit and Privacy Panel for Health and Social Care, respectively. Findings from this study will be presented at academic and clinical conferences, and to the funders and other interested parties as appropriate; study findings will also be published in peer-reviewed journals. Publications will be available on the EAVE II website (https://www.ed.ac.uk/usher/eave-ii/key-outputs/our-publications), alongside lay summaries and infographics aimed at the general public. Press releases will also be considered, if appropriate.

CORE (COnnecting REpositories)